Harvard Apparatus Regenerative Technology, Inc.

For the period ended Mar 31, 2026. Filed May 13, 2026.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2026 · Filed May 13, 2026

HRGNStored price and day change unavailable

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Condensed Consolidated Balance Sheets

(in thousands, except share and par value data)

	March 31,	December 31,
	2026	2025
(Unaudited)
ASSETS
Current assets:
Cash and cash equivalents	$419	$1,352
Accounts receivable	16	16
Inventory	15	16
Prepaid research and development	18	18
Prepaid expenses and other current assets	405	427
Total current assets	873	1,829
Property, plant and equipment, net	5	6
Right-of-use assets, net	168	195
Long-term prepaid contracts	752	647
Total assets	$1,798	$2,677
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$239	$454
Accrued and other current liabilities	839	532
Deferred revenue	340	252
Insurance premium financing payable	115	183
Operating lease liability	118	113
Total current liabilities	1,651	1,534
Operating lease liability, net of current portion	55	86
Total liabilities	1,706	1,620
Commitments and contingencies (Note 6)
Stockholders’ equity:
Common stock, par value $0.01 per share, 60,000,000 shares authorized; 17,580,744 shares issued and outstanding at each of March 31, 2026 and December 31, 2025	176	176
Additional paid-in capital	108,082	107,450
Accumulated deficit	(108,158)	(106,557)
Accumulated other comprehensive loss	(8)	(12)
Total stockholders’ equity	92	1,057
Total liabilities and stockholders’ equity	$1,798	$2,677

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.